ALGS — Aligos Therapeutics Balance Sheet
0.000.00%
- $33.32m
- -$23.46m
- $3.95m
Annual balance sheet for Aligos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 244 | 191 | 126 | 136 | 56.9 |
Total Other Current Assets | |||||
Total Current Assets | 250 | 204 | 134 | 141 | 62.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 14.9 | 15 | 12.5 | 9.82 | 7.33 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 265 | 235 | 147 | 152 | 70.1 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 30.3 | 39 | 33.1 | 23.9 | 21.7 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 45.3 | 50.6 | 42.8 | 59.4 | 99.1 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 220 | 185 | 104 | 92.1 | -29 |
Total Liabilities & Shareholders' Equity | 265 | 235 | 147 | 152 | 70.1 |
Total Common Shares Outstanding |